Roivant Sciences (ROIV) to Release Earnings on Tuesday

Roivant Sciences (NASDAQ:ROIV - Get Free Report) will release its earnings data before the market opens on Tuesday, November 12th. Analysts expect Roivant Sciences to post earnings of ($0.21) per share for the quarter. Investors interested in registering for the company's conference call can do so using this link.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The company reported $0.12 earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.33. The company had revenue of $55.10 million during the quarter, compared to analysts' expectations of $30.72 million. Roivant Sciences had a net margin of 2,991.75% and a negative return on equity of 17.23%. Roivant Sciences's revenue for the quarter was up 155.1% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.38) earnings per share. On average, analysts expect Roivant Sciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Roivant Sciences Stock Up 1.1 %

Shares of NASDAQ ROIV traded up $0.13 during mid-day trading on Tuesday, reaching $11.66. 2,531,828 shares of the company's stock traded hands, compared to its average volume of 5,855,325. The company has a debt-to-equity ratio of 0.05, a current ratio of 27.91 and a quick ratio of 27.91. The business has a 50-day simple moving average of $11.81 and a 200 day simple moving average of $11.27. Roivant Sciences has a 1-year low of $8.47 and a 1-year high of $13.06. The stock has a market cap of $8.62 billion, a P/E ratio of 2.07 and a beta of 1.24.

Analysts Set New Price Targets

A number of equities analysts have commented on ROIV shares. Bank of America boosted their price target on shares of Roivant Sciences from $12.00 to $12.50 and gave the stock a "neutral" rating in a research note on Wednesday, September 11th. Cantor Fitzgerald restated an "overweight" rating on shares of Roivant Sciences in a research note on Thursday, September 19th. Piper Sandler raised their target price on shares of Roivant Sciences from $20.00 to $22.00 and gave the stock an "overweight" rating in a research note on Wednesday, July 10th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $18.00 price objective on shares of Roivant Sciences in a report on Thursday, September 19th. One analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $17.39.

Insiders Place Their Bets

In other news, COO Eric Venker sold 100,000 shares of the business's stock in a transaction that occurred on Monday, October 21st. The stock was sold at an average price of $11.65, for a total value of $1,165,000.00. Following the transaction, the chief operating officer now directly owns 617,470 shares of the company's stock, valued at $7,193,525.50. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO Matthew Gline sold 1,983,257 shares of the company's stock in a transaction dated Monday, September 23rd. The shares were sold at an average price of $11.79, for a total transaction of $23,382,600.03. Following the transaction, the chief executive officer now owns 17,870,543 shares in the company, valued at approximately $210,693,701.97. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Eric Venker sold 100,000 shares of the stock in a transaction that occurred on Monday, October 21st. The shares were sold at an average price of $11.65, for a total transaction of $1,165,000.00. Following the transaction, the chief operating officer now directly owns 617,470 shares of the company's stock, valued at $7,193,525.50. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 3,577,309 shares of company stock valued at $42,151,184 over the last quarter. Insiders own 7.90% of the company's stock.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.